News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,511 Results
Type
Article (14294)
Company Profile (281)
Press Release (254936)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79608)
Career Advice (153)
Deals (13252)
Drug Delivery (35)
Drug Development (50478)
Employer Resources (31)
FDA (5739)
Job Trends (5145)
News (144561)
Policy (10042)
Tag
Academia (916)
Accelerated approval (3)
Adcomms (13)
Allergies (52)
Alliances (21705)
ALS (69)
Alzheimer's disease (854)
Antibody-drug conjugate (ADC) (110)
Approvals (5766)
Artificial intelligence (134)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4564)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (61)
Brain cancer (20)
Breast cancer (165)
Cancer (1546)
Cardiovascular disease (122)
Career advice (134)
Career pathing (2)
CAR-T (127)
Cell therapy (349)
Cervical cancer (9)
Clinical research (41216)
Collaboration (569)
Compensation (286)
Complete response letters (13)
COVID-19 (1036)
CRISPR (48)
C-suite (173)
Cystic fibrosis (78)
Data (1654)
Denatured (11)
Depression (32)
Diabetes (146)
Diagnostics (1307)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (88)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (96)
Earnings (30303)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48909)
Executive appointments (479)
FDA (6526)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (526)
Gene editing (107)
Generative AI (10)
Gene therapy (277)
GLP-1 (375)
Government (1084)
Grass and pollen (2)
Guidances (75)
Healthcare (6597)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (20)
Infectious disease (1103)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7296)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (215)
Leadership (3)
Legal (1389)
Liver cancer (34)
Lung cancer (212)
Lymphoma (107)
Machine learning (5)
Management (7)
Manufacturing (148)
MASH (65)
Medical device (2616)
Medtech (2617)
Mergers & acquisitions (6308)
Metabolic disorders (416)
Multiple sclerosis (55)
NASH (13)
Neurodegenerative disease (78)
Neuropsychiatric disorders (26)
Neuroscience (1291)
NextGen: Class of 2025 (2024)
Non-profit (852)
Now hiring (23)
Obesity (201)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (126)
Partnered (8)
Patents (141)
Patient recruitment (85)
Peanut (35)
People (25717)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14565)
Phase II (19181)
Phase III (12106)
Pipeline (1007)
Policy (49)
Postmarket research (852)
Preclinical (6174)
Press Release (30)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (303)
Real estate (1419)
Recruiting (12)
Regulatory (8690)
Reports (18)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (6)
RNA editing (8)
RSV (10)
Schizophrenia (64)
Series A (103)
Series B (71)
Service/supplier (1)
Sickle cell disease (43)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1978)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (219)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (85)
Last 7 days (600)
Last 30 days (2110)
Last 365 days (19340)
2025 (7514)
2024 (20554)
2023 (22415)
2022 (26823)
2021 (27809)
2020 (23367)
2019 (16237)
2018 (11753)
2017 (13752)
2016 (11840)
2015 (14359)
2014 (10401)
2013 (7499)
2012 (7548)
2011 (7627)
2010 (7439)
Location
Africa (149)
Alabama (44)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17367)
Australia (2949)
California (4201)
Canada (1199)
China (380)
Colorado (160)
Connecticut (157)
Delaware (112)
Europe (37408)
Florida (512)
Georgia (128)
Idaho (16)
Illinois (245)
India (10)
Indiana (94)
Iowa (3)
Japan (84)
Kansas (64)
Kentucky (5)
Louisiana (4)
Maine (11)
Maryland (503)
Massachusetts (3332)
Michigan (77)
Minnesota (157)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1024)
New Mexico (12)
New York (1114)
North Carolina (580)
North Dakota (6)
Northern California (1878)
Ohio (118)
Oklahoma (9)
Oregon (21)
Pennsylvania (785)
Puerto Rico (6)
Rhode Island (19)
South America (209)
South Carolina (5)
Southern California (1604)
Tennessee (26)
Texas (487)
United States (14270)
Utah (56)
Virginia (87)
Washington D.C. (32)
Washington State (371)
Wisconsin (20)
269,511 Results for "dyne therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys 51 in a patient population amenable to exon 51 skipping.
March 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
April 24, 2025
·
8 min read
Press Releases
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 8, 2025
·
8 min read
Press Releases
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
April 16, 2025
·
7 min read
Press Releases
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
March 11, 2025
·
1 min read
Press Releases
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
March 20, 2025
·
5 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14, 2025
April 15, 2025
·
2 min read
Press Releases
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
January 21, 2025
·
6 min read
Press Releases
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
February 17, 2025
·
5 min read
Press Releases
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
March 17, 2025
·
11 min read
1 of 26,952
Next
